Bioventus (NYSE:BVS) Coverage Initiated by Analysts at Barrington Research

Barrington Research began coverage on shares of Bioventus (NYSE:BVS) in a research note released on Monday morning, MarketBeat Ratings reports. The brokerage issued an outperform rating and a $13.00 target price on the stock.

Bioventus Stock Up 0.1%

Shares of NYSE:BVS opened at $8.52 on Monday. The company has a current ratio of 1.41, a quick ratio of 0.99 and a debt-to-equity ratio of 1.85. The stock has a fifty day simple moving average of $7.72 and a two-hundred day simple moving average of $7.28. Bioventus has a 12-month low of $5.81 and a 12-month high of $11.25. The stock has a market capitalization of $705.14 million, a price-to-earnings ratio of -13.97 and a beta of 0.80.

Insider Buying and Selling

In other Bioventus news, Director Guy P. Nohra sold 10,000 shares of the firm’s stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $7.57, for a total transaction of $75,700.00. Following the completion of the sale, the director directly owned 116,610 shares in the company, valued at approximately $882,737.70. This trade represents a 7.90% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 33.00% of the company’s stock.

Hedge Funds Weigh In On Bioventus

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Geode Capital Management LLC grew its holdings in shares of Bioventus by 1.8% in the fourth quarter. Geode Capital Management LLC now owns 1,120,238 shares of the company’s stock worth $8,337,000 after acquiring an additional 19,388 shares during the period. Legato Capital Management LLC boosted its position in Bioventus by 1,042.8% in the fourth quarter. Legato Capital Management LLC now owns 137,562 shares of the company’s stock worth $1,023,000 after purchasing an additional 125,525 shares during the last quarter. Truist Financial Corp bought a new stake in shares of Bioventus during the 4th quarter valued at about $93,000. Allspring Global Investments Holdings LLC increased its position in shares of Bioventus by 9.6% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 71,688 shares of the company’s stock valued at $533,000 after purchasing an additional 6,268 shares during the last quarter. Finally, SG Americas Securities LLC bought a new position in shares of Bioventus in the 4th quarter worth approximately $80,000. Institutional investors own 62.94% of the company’s stock.

About Bioventus

Bioventus, Inc (NYSE: BVS) is a global medical technology company focused on providing innovative therapeutic solutions to enhance patient care in musculoskeletal health. The company develops, manufactures, and markets a range of products designed to promote bone healing, support joint health, and relieve pain non-invasively. Bioventus leverages biologic and biophysical approaches to deliver effective therapies that aim to accelerate recovery times and improve overall patient outcomes.

Bioventus’s product portfolio includes its flagship EXOGEN® Bone Healing System, an ultrasound-based device indicated for non-union fractures and fracture healing enhancement.